Century Therapeutics is a biotechnology company advancing regenerative cell therapies aimed at curing serious diseases. Its lead asset, CNTY-813, is an engineered beta islet cell program designed to provide a potentially curative treatment for Type 1 diabetes by restoring insulin-producing capacity. The company reports rapid progress on this program and plans to accelerate R&D activities with newly secured capital. Beyond CNTY-813, Century indicates ambitions to expand a pipeline of truly transformative cell-based therapies, though specific additional candidates were not detailed in the article. Century’s execution momentum has attracted strong investor interest, resulting in an oversubscribed financing round. The $135 million private placement substantially enhances the firm’s balance sheet and will fund preclinical and clinical development of CNTY-813 and related platform work.

Total raised

$605M

Funding rounds

4

Latest round

Equity

Latest activity

Jan 2026